William Guyer Sells 8,233 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider William Guyer sold 8,233 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $35.99, for a total transaction of $296,305.67. Following the completion of the transaction, the insider owned 2,231 shares in the company, valued at approximately $80,293.69. The trade was a 78.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

William Guyer also recently made the following trade(s):

• On Tuesday, February 3rd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $40.87, for a total transaction of $817,400.00.
• On Tuesday, January 6th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $35.18, for a total transaction of $703,600.00.

Corcept Therapeutics Stock Down 0.5%

Shares of NASDAQ CORT traded down $0.17 during midday trading on Friday, hitting $33.87. The stock had a trading volume of 1,230,010 shares, compared to its average volume of 2,217,244. The business’s 50 day moving average is $40.56 and its 200-day moving average is $64.73. Corcept Therapeutics Incorporated has a 52 week low of $28.66 and a 52 week high of $117.33. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. The company has a market cap of $3.60 billion, a P/E ratio of 41.31 and a beta of 0.29.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The firm had revenue of $202.13 million for the quarter, compared to the consensus estimate of $254.94 million. During the same period last year, the business earned $0.26 EPS. Corcept Therapeutics’s revenue was up 11.1% on a year-over-year basis. As a group, analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: COR T’s Korlym revenue momentum: Zacks highlights a 13% Y/Y sales rise for Korlym in 2025 and projects 2026 revenue of $900M–$1B, suggesting solid underlying product sales even as competitive and legal risks persist. Korlym revenue article
• Neutral Sentiment: Short‑interest data published for early March appears inconsistent/zero (likely a data/reporting glitch) and does not provide clear evidence of increased shorting pressure at this time — investors should treat those figures cautiously. (Multiple short‑interest entries in news feed showed 0 shares / NaN changes.)
• Negative Sentiment: Hagens Berman and other firms: A securities class action (Allegheny County Employees’ Retirement System v. Corcept et al.) was flagged this week alleging the company and executives misled investors, citing FDA warnings and “evidence gaps” around the Relacorilant NDA that previously triggered a ~50% stock drop. Lead‑plaintiff deadline is April 21, 2026. Hagens Berman notice
• Negative Sentiment: Multiple plaintiff firms (Bronstein, Rosen, Pomerantz, Schall, Glancy, DJS, ClaimsFiler, etc.) have issued alerts encouraging investors to join/lead the class action based on purchases between Oct 31, 2024 and Dec 30, 2025 — this amplifies media attention and could increase settlement/defense costs and management distraction. Example: Bronstein notice. Bronstein notice
• Negative Sentiment: Schall/Rosen/Pomerantz & others reiterate class‑period and April 21 deadline; aggregated press releases increase likelihood of large plaintiff turnout and publicity — a material near‑term catalyst pressuring the stock. Example: Schall Law Firm reminder. Schall Law Firm notice

Analyst Upgrades and Downgrades

Several research firms recently commented on CORT. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a report on Wednesday, December 31st. Zacks Research lowered shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Truist Financial set a $50.00 price objective on shares of Corcept Therapeutics in a research report on Wednesday, December 31st. Finally, Canaccord Genuity Group raised their target price on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, January 23rd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $77.17.

Institutional Trading of Corcept Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SHP Wealth Management bought a new position in Corcept Therapeutics in the fourth quarter worth approximately $72,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Corcept Therapeutics in the 4th quarter worth $8,757,000. Virtu Financial LLC bought a new position in Corcept Therapeutics in the 4th quarter worth $456,000. Invesco Ltd. lifted its position in Corcept Therapeutics by 11.5% during the fourth quarter. Invesco Ltd. now owns 816,996 shares of the biotechnology company’s stock valued at $28,431,000 after purchasing an additional 84,413 shares in the last quarter. Finally, FAS Wealth Partners Inc. grew its holdings in Corcept Therapeutics by 0.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 310,018 shares of the biotechnology company’s stock valued at $10,789,000 after purchasing an additional 1,700 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.